We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteome-Based Marker Classifies Chronic Kidney Disease Progression

By LabMedica International staff writers
Posted on 26 Jul 2016
Print article
Image: Capillary electrophoresis–mass spectrometry apparatus (Photo courtesy of the Dovichi Group).
Image: Capillary electrophoresis–mass spectrometry apparatus (Photo courtesy of the Dovichi Group).
Chronic kidney disease (CKD) progression is currently assessed by a decline in estimated glomerular filtration rate (eGFR) and/or an increase in urinary albumin excretion (UAE) though these markers are considered either to be late-stage markers or to have low sensitivity or specificity.

Sometimes the patients have not even been aware of their impaired renal function, until they are in need of a renal replacement therapy, either dialysis or transplantation. Then the diagnosis comes as a shock, because the patients usually learn that various interventions such as a special diet, but also medication with angiotensin-converting-enzyme (ACE) inhibitors might have delayed, perhaps even prevented, end-stage renal disease.

A large team of international scientists led by those at Mosaiques Diagnostics GmbH (Hanover, Germany) collected data from CKD patients and the cohort consisted of 2,672 patients from previous studies. Stages of CKD were defined on the basis of the eGFR, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. More than 75% of the patients suffered from diabetes mellitus while 280 other patients had hypertension, three had membranous glomerulonephritis, 30 had unknown CKD and 313 were healthy individuals. Sample collection and analysis of urine samples was done using capillary electrophoresis–mass spectrometry. The CKD273 classifier is a support vector machine (SVM) classification model based on the amplitudes of 273 urinary peptides, which allows the calculation of a classification score for the presence and progression of CKD.

Of these, 394 individuals displayed a decline in eGFR of more than 5 mL/min/1.73 m2/year (progressors) and the remaining individuals were considered non-progressors. For all samples, UAE values and the urinary peptide CKD273 classification scores were obtained. To assess UAE values and CKD273 scores at different disease stages, the cohort was divided according to baseline eGFRs of ≥80, 70–79, 60–69, 50–59, 40–49, 30–39 and less than 29 mL/min/1.73 m2. In addition, areas under the curve for CKD273 and UAE were calculated.

The investigators found that in early stage CKD, the urinary proteome-based classifier performed significantly better than UAE in detecting progressors. In contrast, UAE performed better in patients with late-stage CKD. No significant difference in performance was found between CKD273 and UAE in patients with moderately reduced renal function. In some patients with an eGFR more than 60 mL/min/1.73 m2 and an UAE between 30 and 300 mg/g, a rapid eGFR decline of more than 15 ml/min/1.73 m2 takes place, while in others the eGFR stays stable and the disease does not progress.

The authors concluded that their study also allowed assessment of its practical implementation: to date, more than 1,500 patients have been evaluated using CKD273 in the study. The result is obtained typically within three days, hence within a similar time frame as for albuminuria. Because the CE-MS analysis is a high-end technology, in contrast to the microalbuminuria test, the cost is higher. However, health economic calculations indicate that CKD273 classifier analysis, when used for the detection of early stage CKD, demonstrated cost-effectiveness. The study was published on July 6, 2016, in the journal NTD (Nephrology Dialysis Transplantation).

Related Links:
Mosaiques Diagnostics

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.